Israeli Group to Study MDMA Therapy for October 7 Survivors With PTSD

Israeli Group to Study MDMA Therapy for October 7 Survivors With PTSD

A group of 400 Israeli survivors of the October 7 Hamas attack, including civilians, released hostages, and soldiers, could be offered MDMA-assisted psychotherapy in a potentially trailblazing study to commence later this year.

“Our goal is to create a therapy model that can serve universally, with the intention and prayer to help people,” said Dr. Keren Tzarfaty, CEO and co-founder of MAPS Israel, which is already running trials evaluating MDMA-assisted therapy for the treatment of post-traumatic stress disorder, depression, and eating disorders. “We hope it will demonstrate high levels of safety and effectiveness and enable us to offer the program in other places over the region and the world, not only to treat PTSD, but to help people open their hearts and expand their minds.”

Dr. Rick Doblin, founding president of the U.S.-based MAPS and a longtime advocate for using psychedelic therapy in the Israeli–Palestinian conflict, said that the study would serve as a seminal piece of research into whether psychedelic-assisted therapy can help large groups of traumatized people.

Read More »

Scientific Misconduct and Fraud: The Final Nail in Psychiatry’s Antidepressant Coffin

“. . . if the major media picks up on this story, they will have the chance to report on what arguably is the worst—and most harmful—scandal in American medical history”

Robert Whitaker, publisher of madinamerica.com, January 3, 2024

Historically, there have always been some patients who report that any treatment for depression—including bloodletting—has worked for them, but science demands that for a treatment to be deemed truly effective, it must work better than a placebo or the passage of time without any treatment. This is especially important for antidepressant drugs—including Prozac, Zoloft, and other selective serotonin reuptake inhibitors (SSRIs), as well as Effexor, Cymbalta, and other serotonin and norepinephrine reuptake inhibitors (SNRIs)—because all of these drugs have uncontroversial troubling side effects.

Scientific Misconduct and Fraud: The Final Nail in Psychiatry’s Antidepressant Coffin

Related:

Once Radical Critiques of Psychiatry are Now Mainstream, So What Remains Taboo?

Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here’s What’s Next

Hundreds of Biden administration employees plan to WALK OUT of their jobs next week in protest of his support for Israel in Hamas war after

Hundreds of Biden administration employees and federal staffers from more than two dozen agencies are set to walk off the job next week in protest of the White House’s handling of the Middle East crisis.

Hundreds of Biden administration employees plan to WALK OUT of their jobs next week in protest of his support for Israel in Hamas war after

Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here’s What’s Next

Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here’s What’s Next

Yet one glaring problem remains. Despite promising clinical results, no one knows exactly how psychedelic drugs work in the brain. Examining their actions on brain cells isn’t just an academic curiosity. It could give rise to variants that maintain antidepressant properties without the high. And because hallucinogens substantially alter our perception [management?!] of the world, they could be powerful tools for investigating the neurobiology behind consciousness.

This year, scientists found another common themepsychedelics seem to “reset” the brain to a more youthful state, at least in mice. Like humans, mice have an adolescent critical period, during which their brains are highly malleable and can easily rewire neural circuits, but the window closes after adulthood.

An earlier study showed that MDMA reopens the critical window in adult mice, so that they change their “personality.” Mice raised alone are often introverted and prefer to keep to themselves in adulthood. A dose of MDMA increased their willingness to snuggle with other mice—essentially, they learned to associate socializing with happiness, concluded the study.

It’s not that surprising. MDMA is well-known to promote empathy and bonding. The new study, by the same team, extended their early results to four psychedelics that don’t trigger fuzzy feelings—LSD, ketamine, psilocybin, and ibogaine. Similar to MDMA, adult mice raised alone changed their usual preference for solitude when treated with any of the drugs. Because habits are hard to change in adulthood—for mice and men—the drugs may have reopened the critical period, allowing the brain to more easily rewire neural connections based on new experiences.

These are just early results. But psychedelic research is gaining a new ally—artificial intelligence. Algorithms that predict protein structure, combined with rational drug design, could generate psychedelics that retain their psychiatric benefits without the high.

H/T: The Most Revolutionary Act

Related:

Psychoanalytic roots of CIA psychoprofiling/pseudoscience

Meaghan thought psychedelic therapy could help her PTSD. Instead it was the start of a nightmare

Why is the American right suddenly so interested in psychedelic drugs

What if a Pill Can Change Your Politics or Religious Beliefs? (archived)

Do Psychedelic Trips Change Your Political Views? (archived)

Dan Crenshaw’s measure greenlighting psychedelics to treat PTSD part of defense bill + More

The legislation would allow supervised clinical studies with active-duty members.

Dan Crenshaw’s measure greenlighting psychedelics to treat PTSD part of defense bill

Related:

First-ever provision for psychedelic studies included in defense bill

National Defense Authorization Act, pp. 402-406, p. 1817 ($50,311 allocated for R&D)

CIA MKULTRA / Mind Control Collection

FDA Weighs New Application To Approve MDMA As First-Ever Psychedelic Medicine For PTSD + More About MAPS

FDA Weighs New Application To Approve MDMA As First-Ever Psychedelic Medicine For PTSD + More About MAPS

A psychedelics-focused drug development company is officially asking the Food and Drug Administration (FDA) to review an application to approve MDMA as a prescription medication for the treatment of post-traumatic stress disorder (PTSD).

The MAPS Public Benefit Corporation (MAPS PBC) announced on Tuesday that it submitted the new drug application (NDA) to FDA, requesting an expedited review given that the agency previously designated the psychedelic as a breakthrough therapy.

FDA Weighs New Application To Approve MDMA As First-Ever Psychedelic Medicine For PTSD

H/T: The Most Revolutionary Act

The MAPS Public Benefit Corporation is subsidiary of Multidisciplinary Association for Psychedelic Studies. MAPS was founded by Rick Doblin.*

Related:

Read More »

Is China really buying up U.S. farmland? Here’s what we found

Is China really buying up U.S. farmland? Here’s what we found

A review by NBC News of thousands of documents filed with the U.S. Department of Agriculture, however, shows very few purchases by Chinese buyers in the past year and a half — fewer than 1,400 acres in a country with 1.3 billion acres of agricultural land. In fact, the total amount of U.S. agricultural land owned by Chinese interests is less than three-hundredths of 1%.

CDC: Illicit biolab found in California posed no dangers, while FDA recalls certain pregnancy, ovulation, and UTI tests

Jesalyn Harper, the only full-time code enforcement officer for the small, agricultural city of Reedley in California’s Central Valley, was responding to a complaint about vehicles parked in the loading dock of a cold-storage warehouse when she noticed a foul smell and saw a garden hose snaking into the old building.

CDC: Illicit biolab found in California posed no dangers

Related:

Do not use certain pregnancy, ovulation, UTI tests, FDA warns

The tests may have been distributed under brand names such as AC&C, HealthyWiser, Home Health US and Prestige Biotech.